{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:00:51Z","timestamp":1768485651473,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite advancements in antiretroviral therapy (ART) for people with HIV, barriers to adherence remain, potentially leading to long-term gaps in adherence known as treatment interruptions. These treatment interruptions are associated with viral rebound and can impact the effectiveness of the subsequent regimen and the long-term health of the individual. We aimed to characterize unplanned ART treatment interruptions in the OPERA<jats:sup>\u00ae<\/jats:sup> cohort and investigate virologic outcomes among individuals who resumed treatment with bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We identified adults with HIV-1 who were active in care and on an oral ART regimen with \u2265\u20092 antiretrovirals, including \u2265\u20091 anchor agent, between 30JUN2021 and 31AUG2023. Individuals with \u2265\u20091 period of \u2265\u200945 days without any ART, based on supply from last prescription, were considered to have experienced a treatment interruption. Individuals who resumed treatment by 31AUG2023 were defined as having experienced a treatment interruption with resumption. Each interruption observed during the study period was described, allowing for multiple interruptions per person. Treatment interruptions, pre-interruption regimens, and post-interruption regimens were described. Among individuals who resumed treatment with B\/F\/TAF, virologic outcomes were investigated through 29FEB2024 using Kaplan-Meier methods. All analyses were repeated with treatment interruption definitions of \u2265\u200960 and \u2265\u200990 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 76,883 people for whom a treatment interruption could be observed, 8,550 (11%) experienced\u2009\u2265\u20091 period of \u2265\u200945 days without any ART. By 31AUG2023, 4,163 (49%) individuals resumed treatment (mean: 1.25 per person) and were included in the study population. The median age was 44 years, 81% were male, 52% Black, 41% White, and 18% Hispanic. Median time since HIV diagnosis was 118 months. B\/F\/TAF was the most common pre- and post-interruption regimen (49% and 51%, respectively). The cumulative probability of achieving virologic suppression on B\/F\/TAF was 68% (95% CI: 57, 78) when the viral load measurement was \u2265\u2009200 copies\/mL at resumption.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Treatment interruptions occurred in 11% of ART users in routine clinical care during the 26-month study period. Despite treatment interruption increasing the risk for viral rebound, most individuals who resumed treatment with B\/F\/TAF were able to achieve virologic suppression or avoid virologic failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12981-025-00769-x","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T13:23:02Z","timestamp":1753104182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir\/emtricitabine\/tenofovir alafenamide"],"prefix":"10.1186","volume":"22","author":[{"given":"Karam","family":"Mounzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Osterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricky K.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Pierone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neia","family":"Prata Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"1","key":"769_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1916753","volume":"383","author":"AS Fauci","year":"2020","unstructured":"Fauci AS, Lane HC. Four decades of HIV\/AIDS \u2014 much accomplished, much to do. N Engl J Med. 2020;383(1):1\u20134.","journal-title":"N Engl J Med"},{"issue":"9903","key":"769_CR2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525\u201333.","journal-title":"Lancet"},{"key":"769_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"769_CR4","first-page":"91","volume":"10","author":"G Dubrocq","year":"2018","unstructured":"Dubrocq G, Rakhmanina N. Antiretroviral therapy interruptions: impact on HIV treatment and transmission. HIV AIDS (Auckl). 2018;10:91\u2013101.","journal-title":"HIV AIDS (Auckl)"},{"issue":"sup1","key":"769_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/09540121.2018.1469725","volume":"30","author":"K Engler","year":"2018","unstructured":"Engler K, Lenart A, Lessard D, Toupin I, Lebouche B. Barriers to antiretroviral therapy adherence in developed countries: a qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure. AIDS Care. 2018;30(sup1):17\u201328.","journal-title":"AIDS Care"},{"issue":"11","key":"769_CR6","doi-asserted-by":"publisher","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported barriers to adherence to antiretroviral therapy: A systematic review and Meta-Analysis. PLoS Med. 2016;13(11):e1002183.","journal-title":"PLoS Med"},{"key":"769_CR7","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 2024 [updated 02\/27\/2024. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"769_CR8","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Department of Health and Human Services2021 [updated June 3, 2021. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf"},{"issue":"10","key":"769_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/cid\/ciu603","volume":"59","author":"MJ Mugavero","year":"2014","unstructured":"Mugavero MJ, Westfall AO, Cole SR, Geng EH, Crane HM, Kitahata MM, et al. Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. Clin Infect Dis. 2014;59(10):1471\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"769_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1086\/595705","volume":"48","author":"MJ Mugavero","year":"2009","unstructured":"Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, et al. Missed visits and mortality among patients Establishing initial outpatient HIV treatment. Clin Infect Dis. 2009;48(2):248\u201356.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"769_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1086\/516778","volume":"44","author":"TP Giordano","year":"2007","unstructured":"Giordano TP, Gifford AL, White AC Jr., Suarez-Almazor ME, Rabeneck L, Hartman C, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"769_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/aid.2010.0268","volume":"27","author":"A Tripathi","year":"2011","unstructured":"Tripathi A, Youmans E, Gibson JJ, Duffus WA. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study. AIDS Res Hum Retroviruses. 2011;27(7):751\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"769_CR13","doi-asserted-by":"publisher","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the united States and Canada. PLoS ONE. 2013;8(12):e81355.","journal-title":"PLoS ONE"},{"issue":"7","key":"769_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. 2018;24(7):923\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"769_CR15","doi-asserted-by":"publisher","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","volume":"14","author":"KE Clarridge","year":"2018","unstructured":"Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, et al. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and Immunologic parameters in infected individuals. PLoS Pathog. 2018;14(1):e1006792.","journal-title":"PLoS Pathog"},{"issue":"4","key":"769_CR16","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019;6(4):e259\u201368.","journal-title":"Lancet HIV"},{"issue":"5","key":"769_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/COH.0000000000000484","volume":"13","author":"Y Wen","year":"2018","unstructured":"Wen Y, Bar KJ, Li JZ. Lessons learned from HIV antiretroviral treatment interruption trials. Curr Opin HIV AIDS. 2018;13(5):416\u201321.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"769_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/QAD.0000000000002113","volume":"33","author":"JSY Lau","year":"2019","unstructured":"Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. AIDS. 2019;33(5):773\u201391.","journal-title":"AIDS"},{"issue":"9","key":"769_CR19","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","volume":"38","author":"GA McComsey","year":"2021","unstructured":"McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-World adherence to antiretroviral therapy among HIV-1 patients across the united States. Adv Ther. 2021;38(9):4961\u201374.","journal-title":"Adv Ther"},{"key":"769_CR20","doi-asserted-by":"crossref","unstructured":"Redd AD, Mukonda E, Hu N-C, Philips TK, Zerbe A, Lesosky M et al. ART adherence, resistance, and Long-term HIV viral suppression in postpartum women. Open Forum Infect Dis. 2020;7(10).","DOI":"10.1093\/ofid\/ofaa346"},{"key":"769_CR21","doi-asserted-by":"publisher","first-page":"232595822211402","DOI":"10.1177\/23259582221140208","volume":"21","author":"FMD Maggiolo","year":"2022","unstructured":"Maggiolo FMD, Valenti DB, Teocchi RB, Comi LMD, Di Filippo EMD, Rizzi MMD. Real world data on forgiveness to uncomplete adherence to bictegravir\/ emtricitabine\/tenofovir Alafenamide. J Int Assoc Provid AIDS Care. 2022;21:23259582221140208.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"769_CR22","doi-asserted-by":"publisher","first-page":"232595822211018","DOI":"10.1177\/23259582221101815","volume":"21","author":"F Maggiolo","year":"2022","unstructured":"Maggiolo F, Valenti D, Teocchi R, Comi L, Filippo ED, Rizzi M. Adherence to and forgiveness of 3TC\/DTG in a Real-World cohort. J Int Assoc Provid AIDS Care. 2022;21:23259582221101815.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"1","key":"769_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","volume":"17","author":"J Cohen","year":"2020","unstructured":"Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res Therapy. 2020;17(1):12.","journal-title":"AIDS Res Therapy"},{"issue":"5","key":"769_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/QAI.0000000000003594","volume":"98","author":"L Taramasso","year":"2025","unstructured":"Taramasso L, Maggiolo F, Valenti D, Blanchi S, Centorrino F, Comi L, et al. Adherence and forgiveness of two modern ART regimens: lamivudine\/dolutegravir and emtricitabine\/tenofovir alafenamide\/rilpivirine. JAIDS J Acquir Immune Defic Syndr. 2025;98(5):484\u201390.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"769_CR25","unstructured":"Centers for Disease Control and Prevention. HIV, Surveillance Report. vol. 34: Diagnoses of HIV Infection in the United States and Dependent Areas, 2021 2023 [updated 23 May 2023. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/149071"},{"issue":"7","key":"769_CR26","first-page":"449","volume":"11","author":"R Sikka","year":"2005","unstructured":"Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449\u201357.","journal-title":"Am J Manag Care"},{"issue":"13","key":"769_CR27","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1097\/QAD.0000000000003648","volume":"37","author":"JB Angel","year":"2023","unstructured":"Angel JB, Freilich J, Arthurs E, Ban JK, Lachaine J, Chounta V, et al. Adherence to oral antiretroviral therapy in canada, 2010\u20132020. AIDS. 2023;37(13):2031\u201340.","journal-title":"AIDS"},{"issue":"3","key":"769_CR28","doi-asserted-by":"publisher","first-page":"ofac018","DOI":"10.1093\/ofid\/ofac018","volume":"9","author":"K Mounzer","year":"2022","unstructured":"Mounzer K, Brunet L, Fusco JS, Mcnicholl IR, Diaz Cuervo H, Sension M, et al. Advanced HIV infection in treatment Na\u00efve individuals: effectiveness and persistence of recommended Three-Drug regimens. Open Forum Infect Dis. 2022;9(3):ofac018.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"769_CR29","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1365-3156.2011.02828.x","volume":"16","author":"K Kranzer","year":"2011","unstructured":"Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Tropical Med Int Health. 2011;16(10):1297\u2013313.","journal-title":"Tropical Med Int Health"},{"issue":"3","key":"769_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s10461-023-04208-8","volume":"28","author":"P Li","year":"2024","unstructured":"Li P, Prajapati G, Geng Z, Ladage VP, Arduino JM, Watson DL, et al. Antiretroviral treatment gaps and adherence among people with HIV in the U.S. Medicare program. AIDS Behav. 2024;28(3):1002\u201314.","journal-title":"AIDS Behav"},{"issue":"5","key":"769_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/tmi.12690","volume":"21","author":"A Jiamsakul","year":"2016","unstructured":"Jiamsakul A, Kerr SJ, Ng OT, Lee MP, Chaiwarith R, Yunihastuti E, et al. Effects of unplanned treatment interruptions on HIV treatment failure\u2013 results from TAHOD. Tropical Med Int Health. 2016;21(5):662\u201374.","journal-title":"Tropical Med Int Health"},{"issue":"1","key":"769_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12913-017-2172-9","volume":"17","author":"AM Teklu","year":"2017","unstructured":"Teklu AM, Yirdaw KD. Patients who restart antiretroviral medication after interruption remain at high risk of unfavorable outcomes in Ethiopia. BMC Health Serv Res. 2017;17(1):247.","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"769_CR33","first-page":"965","volume":"21","author":"JH Oyugi","year":"2007","unstructured":"Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala. Uganda AIDS. 2007;21(8):965\u201371.","journal-title":"Uganda AIDS"},{"issue":"1","key":"769_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12879-015-1137-z","volume":"15","author":"AA Ahonkhai","year":"2015","unstructured":"Ahonkhai AA, Banigbe B, Adeola J, Onwuatuelo I, Bassett IV, Losina E, et al. High rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in Nigeria. BMC Infect Dis. 2015;15(1):397.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"769_CR35","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/aje\/kwad076","volume":"192","author":"C Thomadakis","year":"2023","unstructured":"Thomadakis C, Yiannoutsos CT, Pantazis N, Diero L, Mwangi A, Musick BS, et al. The effect of HIV treatment interruption on subsequent immunological response. Am J Epidemiol. 2023;192(7):1181\u201391.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"769_CR36","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1097\/QAD.0000000000003859","volume":"38","author":"H Moolla","year":"2024","unstructured":"Moolla H, Davies M-A, Davies C, Euvrard J, Prozesky HW, Fox MP, et al. The effect of care interruptions on mortality in adults resuming antiretroviral therapy. AIDS. 2024;38(8):1198\u2013205.","journal-title":"AIDS"},{"key":"769_CR37","doi-asserted-by":"publisher","first-page":"232595821989953","DOI":"10.1177\/2325958219899534","volume":"19","author":"S Maria","year":"2020","unstructured":"Maria S, Yunihastuti E, Saldi SRF, Djoerban Z. Factors affecting virological outcome when First-Line antiretroviral therapy is reintroduced after unplanned interruption. J Int Association Providers AIDS Care (JIAPAC). 2020;19:2325958219899534.","journal-title":"J Int Association Providers AIDS Care (JIAPAC)"},{"key":"769_CR38","unstructured":"Prevention CfDCa. HIV Surveillance Report: Diagnoses, Deaths, and Prevalence of HIV in the United States and 6 Territories and Freely Associated States, 2022 2024 [updated 21 May 2024. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/156509"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00769-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:47:47Z","timestamp":1757270867000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00769-x","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board (IRB) approval covering patient data contained in the OPERA database was received from Advarra IRB; a waiver of informed consent and authorization for the use of protected health information for patient data was granted (Pro00023648). The study was conducted in accordance with HIPAA and HITECH requirements, which expand upon the ethical principles detailed in the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KM, RKH, and GP are members of the Epidemiology and Clinical Advisory Board of Epividian. KM has received research grants from Gilead Sciences, Merck, Janssen, and GSK\/ViiV Healthcare and honoraria for Speakers Bureau and Advisory Boards from Gilead Sciences, Merck, Janssen and GSK\/ViiV Healthcare; and advisory board participation with Epividian. LB, MDO, JSF, and GPF are employed by Epividian, Inc.; Epividian has had research funded by AIDS Healthcare Foundation, EMD Serono, Gilead Sciences, Janssen Scientific Affairs, LLC, Merck & Co., Theratechnologies Inc., and ViiV Healthcare. RKH has received research grants from Gilead Sciences and ViiV Healthcare, speaker honoraria from ViiV Healthcare, Merck and Gilead Sciences, and advisory board participation with ViiV Healthcare, Gilead Sciences and Epividian. GP has received research funding paid to his institution from GSK\/ViiV Healthcare, NIH\/DAIDS, Gilead Sciences and Precision for Medicine, and is a member of the Epidemiology and Clinical Advisory Board for Epividian. NPM, JG, TL, and MD are employed by Gilead Sciences and hold stock in Gilead Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}